How many clinical trials are studying Digoxin?

3 recruiting trials in our tracked data involve Digoxin.

What conditions is Digoxin being studied for?

In our tracked recruiting trials, Digoxin is being studied in trials for Acute Heart Failure (AHF), Drug Drug Interaction (DDI), Fatty Liver Disease.

Digoxin: clinical trials recruiting now

Q: Is Digoxin FDA-approved?

Yes. According to the FDA drug label available through openFDA, Digoxin is an FDA-approved drug.

Recruiting trials

Conditions studied

US states with sites

Countries

FDA drug label

FDA-approved: Yes. Digoxin appears in the FDA drug-label database. Marketed as Digoxin.
Drug class: Cardiac Glycoside (FDA established pharmacologic class)

FDA-approved use

& USAGE Digoxin is a cardiac glycoside indicated for: Treatment of mild to moderate heart failure in adults. ( 1.1 ) Increasing myocardial contractility in pediatric patients with heart failure. ( 1.2 ) Control of resting ventricular rate in patients with chronic atrial fibrillation in adults. ( 1.3 ) 1.1 Heart Failure in Adults Digoxin is indicated for the treatment of mild to moderate heart failure in adults. Digoxin increases left ventricular ejection fraction and improves heart failure symptoms as evidenced by improved exercise capacity and decreased heart failure-related hospitalizations and emergency care, while having no effect on mortality. Where possible, digoxin should be used in combination with a diuretic and an angiotensin-converting enzyme (ACE) inhibitor. 1.2 Heart Failure in Pediatric Patients Digoxin increases myocardial contractility in pediatric patients with heart failure. 1.3 Atrial Fibrillation in Adults Digoxin is indicated for the control of ventricular response rate in adult patients with chronic atrial fibrillation.

FDA recalls / enforcement

Reason (FDA)	Classification	Status	Initiated
Cross Contamination with Other Products:(mycophenolate mofetil). — Novitium Pharma LLC	Class III (FDA: unlikely to cause harm)	Terminated	2024-03-04
Failed Impurities/Degradation Specifications — Novitium Pharma LLC	Class III (FDA: unlikely to cause harm)	Terminated	2024-03-25

FDA label via openFDA

Phase breakdown

Phase 1 1 Phase 2 1 Phase 4 1

Conditions being studied

Condition	Trials
Acute Heart Failure (AHF)	1
Drug Drug Interaction (DDI)	1
Fatty Liver Disease	1
Fatty Liver Disease, Nonalcoholic	1
Heart failure	1
MASH - Metabolic Dysfunction-Associated Steatohepatitis	1
MASH With Fibrosis	1
MASLD	1
Mash	1
NAFLD	1
NASH	1
Obesity	1
Pharmacokinetics and Pharmacodynamics	1

Recruiting trials involving Digoxin

Digoxin After Acute Heart Failure (DIG-DICA)
NCT07321509 · Phase: Phase 4 · Ages: 18 Years to 120 Years · Sex: All (male and female) · 1 location
Digoxin In NASH (CODIN)
NCT06588699 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 2 locations
Phase I Drug-Drug Interaction Study of UBT251 Injection in Participants With Overweight or Obesity
NCT07785934 · Phase: Phase 1 · Ages: 18 Years to 45 Years · Sex: All (male and female) · 1 location

Common questions

Is Digoxin FDA-approved?

Yes, marketed as Digoxin.

How many recruiting trials involve Digoxin?

3 recruiting trials across 13 conditions.

Is this list of trials complete?

No. For the full record, search ClinicalTrials.gov.